Brief: Zai Lab Receives U.S. FDA Fast Track Designation For Zocilurtatug Pelitecan (Zoci)
11/05/2026 12:02
May 11 (Reuters) - Zai Lab Ltd 9688.HK: ZAI LAB RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR ZOCILURTATUG PELITECAN (ZOCI), A DLL3-TARGETING ADC, FOR TREATMENT OF EXTRAPULMONARY NEUROENDOCRINE CARCINOMAS (EPNECS) Source text: ID:nBw3xc0Tpa Further company coverage: 9688.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zai Lab
See all newsBrief: Zai Lab Agrees To Issue To Investors Aggregate Of 11.3 Million ADSs
Zai Lab's Hong Kong shares hit three-month high on quarterly revenue beat
Brief: U.S. FDA Grants Orphan Drug Designation To Zai Lab’S Dll3-Targeting Adc Zocilurtatug Pelitecan (Zoci) For The Treatment Of Neuroendocrine Carcinomas (Necs)
Brief: Goldman Sachs Group's Long Position In Zai Lab Decreases On May 14, HKEX Filing Shows
Brief: Zai Lab Receives U.S. FDA Fast Track Designation For Zocilurtatug Pelitecan (Zoci)